000164533 001__ 164533
000164533 005__ 20240722121854.0
000164533 0247_ $$2doi$$a10.1002/ana.26416
000164533 0247_ $$2pmid$$apmid:35599344
000164533 0247_ $$2ISSN$$a0364-5134
000164533 0247_ $$2ISSN$$a1531-8249
000164533 0247_ $$2altmetric$$aaltmetric:128772172
000164533 037__ $$aDZNE-2022-01082
000164533 041__ $$aEnglish
000164533 082__ $$a610
000164533 1001_ $$0P:(DE-2719)9001971$$aLiu, Hui$$b0$$eFirst author
000164533 245__ $$aPolygenic resilience modulates the penetrance of Parkinson's disease genetic risk factors.
000164533 260__ $$aHoboken, NJ$$bWiley-Blackwell$$c2022
000164533 3367_ $$2DRIVER$$aarticle
000164533 3367_ $$2DataCite$$aOutput Types/Journal article
000164533 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721637037_12031
000164533 3367_ $$2BibTeX$$aARTICLE
000164533 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164533 3367_ $$00$$2EndNote$$aJournal Article
000164533 500__ $$aCC BY-NC-ND
000164533 520__ $$aThe aim of the current study is to understand why some individuals avoid developing Parkinson's disease (PD) in spite of being at relatively high genetic risk, using the largest datasets of individual-level genetic data available.We calculated polygenic risk score to identify controls and matched PD cases with the highest burden of genetic risk for PD in the discovery cohort (IPDGC, 7,204 PD cases and 9,412 controls) and validation cohorts (COURAGE-PD, 8,968 cases and 7,598 controls; UKBB, 2,639 PD cases and 14,301 controls; AMP-PD, 2,248 cases and 2,817 controls). A genome-wide association study meta-analysis was performed on these individuals to understand genetic variation associated with resistance to disease. We further constructed a polygenic resilience score, performed MAGMA gene-based analyses and functional enrichment analyses.A higher polygenic resilience score was associated with a lower risk for PD (Beta= -0.054, SE = 0.022; P = 0.013). Although no single locus reached genome-wide significance, MAGMA gene-based analyses nominated TBCA as a putative gene. Furthermore, we estimated the narrow-sense heritability associated with resilience to PD (h2 = 0.081, SE = 0.035, P = 0.0003). Subsequent functional enrichment analysis highlighted histone methylation as potential pathway harboring resilience alleles that could mitigate the effects of PD risk loci.The present study represents a novel and comprehensive assessment of heritable genetic variation contributing to PD resistance. We show that a genetic resilience score can modify the penetrance of PD genetic risk factors and therefore protect individuals carrying a high-risk genetic burden from developing PD. This article is protected by copyright. All rights reserved.
000164533 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164533 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164533 650_7 $$2Other$$aParkinson's disease
000164533 650_7 $$2Other$$agenetics
000164533 650_7 $$2Other$$apolygenic risk
000164533 650_7 $$2Other$$aresilience
000164533 7001_ $$0P:(DE-2719)9002232$$aDehestani, Mohammad$$b1$$udzne
000164533 7001_ $$0P:(DE-2719)2810837$$aBlauwendraat, Cornelis$$b2
000164533 7001_ $$aMakarious, Mary B$$b3
000164533 7001_ $$0P:(DE-2719)9001970$$aLeonard, Hampton L$$b4
000164533 7001_ $$aKim, Jonggeol J$$b5
000164533 7001_ $$0P:(DE-2719)9000366$$aSchulte, Claudia$$b6
000164533 7001_ $$00000-0003-3027-5497$$aNoyce, Alastair$$b7
000164533 7001_ $$aJacobs, Benjamin M$$b8
000164533 7001_ $$00000-0002-0253-4116$$aFoote, Isabelle$$b9
000164533 7001_ $$0P:(DE-2719)9000296$$aSharma, Manu$$b10
000164533 7001_ $$aConsortium, International Parkinson's Disease Genomics$$b11$$eCollaboration Author
000164533 7001_ $$aGenetics, Comprehensive Unbiased Risk factor Assessment for$$b12
000164533 7001_ $$aDisease, Environment in Parkinson's$$b13$$eCollaboration Author
000164533 7001_ $$aNalls, Mike$$b14
000164533 7001_ $$aSingleton, Andrew$$b15
000164533 7001_ $$0P:(DE-2719)2320009$$aGasser, Thomas$$b16
000164533 7001_ $$aBandres-Ciga, Sara$$b17
000164533 773__ $$0PERI:(DE-600)2037912-2$$a10.1002/ana.26416$$gp. ana.26416$$n2$$p270-278$$tAnnals of neurology$$v92$$x0364-5134$$y2022
000164533 8564_ $$uhttps://pub.dzne.de/record/164533/files/DZNE-2022-01082.pdf$$yOpenAccess
000164533 8564_ $$uhttps://pub.dzne.de/record/164533/files/DZNE-2022-01082.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000164533 909CO $$ooai:pub.dzne.de:164533$$pdnbdelivery$$pdriver$$popenaire$$pVDB$$popen_access
000164533 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001971$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000164533 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002232$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000164533 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810837$$aExternal Institute$$b2$$kExtern
000164533 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001970$$aExternal Institute$$b4$$kExtern
000164533 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000366$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000164533 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000296$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000164533 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2320009$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b16$$kDZNE
000164533 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164533 9141_ $$y2022
000164533 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000164533 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000164533 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000164533 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000164533 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000164533 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000164533 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN NEUROL : 2021$$d2022-11-30
000164533 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bANN NEUROL : 2021$$d2022-11-30
000164533 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-03$$wger
000164533 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000164533 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-30
000164533 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000164533 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000164533 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000164533 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000164533 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-30
000164533 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-30$$wger
000164533 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000164533 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000164533 9201_ $$0I:(DE-2719)6000018$$kTübingen common$$lTübingen common$$x1
000164533 9201_ $$0I:(DE-2719)5000057$$kExt HIH$$lExt Hertie-Institut für klinische Hirnforschung$$x2
000164533 980__ $$ajournal
000164533 980__ $$aVDB
000164533 980__ $$aI:(DE-2719)1210000
000164533 980__ $$aI:(DE-2719)6000018
000164533 980__ $$aI:(DE-2719)5000057
000164533 980__ $$aUNRESTRICTED
000164533 9801_ $$aFullTexts